Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28086954 | 0.98 | KDM4E (0.46) | KDM4EPOLBAPEX1TDP1FPR2 | |
| SCHEMBL2005829 | 0.81 | FPR2 (0.43) | KDM4EPOLBAPEX1TDP1FPR2 | |
| SCHEMBL3069717 | 0.72 | KDM4E (0.53) | KDM4EPOLBAPEX1TDP1FPR2 | |
| SCHEMBL15230761 | 0.67 | HTT (0.47) | POLBALDH1A1HTT | |
| SCHEMBL3462293 | 0.66 | POLB (0.71) | KDM4EPOLBAPEX1TDP1HTT | |
| SCHEMBL25235716 | 0.66 | SMN1; SMN2 (0.38) | KDM4E | |
| SCHEMBL13908401 | 0.65 | — | — | |
| SCHEMBL3066671 | 0.64 | POLB (1.00) | KDM4EPOLBAPEX1TDP1ALDH1A1 | |
| Benzene SCHEMBL28024132 | 0.64 | POLB (1.00) | KDM4EPOLBAPEX1TDP1ALDH1A1 | |
| SCHEMBL3925724 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101534811-A | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | ORGANON NV (NL) | 2009-09-16 | — | — | CN | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | KDM4E 2478/4885POLB 4217/4885APEX1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.